Rapport
Pneumococcal AMC outcomes and impact evaluation
This evaluation assesses the extent to which the Advanced Market Commitment (AMC) pilot has achieved its stated objectives and the overarching goal to “reduce morbidity and mortality from pneumococcal disease by accelerating the development, availability and uptake of pneumococcal conjugate vaccines (PCVs)”. The AMC pilot was started in 2005 and officially launched in 2007 with a collective US$ 1.5 billion commitment from the Bill and Melinda Gates Foundation, Canada, Italy, Norway, Russian Federation and United Kingdom.
Auteurs
Langues
- Anglais
Année de publication
2016
Type
Rapport
Catégories
- Initiatives mondiales
Maladies
- Infection à pneumocoque
Organisations
- Gavi, l'Alliance du vaccin
Mots-clés
- Suivi de performance
- Planification, budgétisation et financement
Régions de l'OMS
- Région africaine
